Reports studying the efficacy of several RTK inhibitors found the following inhibitors—imatinib, sunitinib, vandetanib, gefitinib, PI3K/mTOR inhibitors, BEZ-235, rapamycin, and p38 MAP kinase inhibitors (SB 202190 and SB 203580)—either inactive or less effective on chordoma cells [49]. Here, MTOR is linked to chordoma.